计算机断层扫描与磁共振成像上肝脏表面结节性定量评估肝纤维化的诊断效能:系统评价与荟萃分析
该系统评价与荟萃分析纳入6项研究,评估肝脏表面结节性(LSN)评分对肝纤维化的诊断效能。LSN评分诊断显著纤维化(F2-4)的汇总敏感度68%、特异度89%、AUC 0.90;诊断进展期纤维化(F3-4)的汇总敏感度88%、特异度78%、AUC 0.89;诊断肝硬化(F4)的汇总敏感度83%、特异度80%、AUC 0.87。结论认为LSN评分在评估肝纤维化分期方面显示出良好的诊断效能,需要进一步研究以改进和标准化LSN评分。
要点
- LSN评分诊断进展期纤维化(F3-4)的汇总敏感度最高(88%),诊断显著纤维化(F2-4)的汇总特异度最高(89%)。
- LSN评分诊断显著纤维化、进展期纤维化和肝硬化的汇总AUC分别为0.90、0.89和0.87。
- LSN评分的诊断效能因界值、成像方式和参考标准而异。
核心结论
- LSN评分在评估肝纤维化分期方面显示出良好的诊断效能;需要进一步研究以改进和标准化LSN评分。
研究设计与样本
- 系统评价与荟萃分析,检索2011年1月至2021年4月发表的相关研究,从168项筛选研究中纳入6项,采用双变量随机效应模型计算汇总敏感度、特异度和HSROC曲线下面积(AUC),并进行亚组分析探讨异质性原因。
诊断标准与关键数值
- 诊断显著纤维化(F2-4):LSN评分汇总敏感度68%(95%CI 45-84%)、特异度89%(95%CI 83-93%)、AUC 0.90(95%CI 0.87-0.92)。
- 诊断进展期纤维化(F3-4):LSN评分汇总敏感度88%(95%CI 60-97%)、特异度78%(95%CI 57-90%)、AUC 0.89(95%CI 0.86-0.91)。
- 诊断肝硬化(F4):LSN评分汇总敏感度83%(95%CI 71-91%)、特异度80%(95%CI 72-85%)、AUC 0.87(95%CI 0.83-0.89)。
- LSN评分界值影响进展期纤维化(p=0.03)和肝硬化(p=0.01)诊断的研究异质性。
- 成像方式(p=0.01)和参考标准(p=0.01)影响肝硬化诊断的研究异质性。
临床应用与阅片要点
- LSN评分可用于CT和MRI上评估肝纤维化分期,阅片时需注意其诊断效能因界值、成像方式和参考标准而异。
局限性
- 需要进一步研究以改进和标准化LSN评分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine the diagnostic performance of the liver surface nodularity (LSN) score for assessment of hepatic fibrosis.
METHODS: Major databases were searched to identify studies reporting the diagnostic performance of the LSN score published from January 2011 to April 2021. The pooled sensitivity and specificity of the LSN score in the diagnosis of significant fibrosis (F2-4), advanced fibrosis (F3-4), and liver cirrhosis (F4) were calculated using a bivariate random-effects model, and the summary areas under the hierarchical summary receiver operating characteristics curve (AUC) for each were calculated. Subgroup analysis was performed to explore the causes of study heterogeneity.
RESULTS: Of 168 screened studies, six were included in the analysis. The pooled sensitivity, specificity, and AUC of the LSN score were 68% (95% confidence interval [CI], 45-84%), 89% (95% CI, 83-93%), and 0.90 (95% CI, 0.87-0.92), respectively, for the diagnosis of significant fibrosis; 88% (95% CI, 60-97%), 78% (95% CI, 57-90%), and 0.89 (95% CI, 0.86-0.91), respectively, for the diagnosis of advanced fibrosis; and 83% (95% CI, 71-91%), 80% (95% CI, 72-85%), and 0.87 (95% CI, 0.83-0.89), respectively, for the diagnosis of liver cirrhosis. Cutoff values of the LSN score affected study heterogeneity in the diagnosis of advanced fibrosis (p = 0.03) and liver cirrhosis (p = 0.01). Imaging modality (p = 0.01) and reference standard (p = 0.01) affected study heterogeneity in the diagnosis of liver cirrhosis.
CONCLUSIONS: The LSN score showed good diagnostic performance in assessing the hepatic fibrosis stage. Additional investigations are needed to improve and standardize the LSN score. Key Points • The liver surface nodularity (LSN) score showed overall good diagnostic performance in assessing hepatic fibrosis. • The pooled sensitivity of the LSN score was highest in the diagnosis of advanced fibrosis (88%; 95% confidence interval [CI], 60-97%), and the pooled specificity was highest in the diagnosis of significant fibrosis (89%; 95% CI, 83-93%). • The diagnostic performance of the LSN score differed according to the cutoff value, imaging modality, and reference standard.
引用
- Heo, Kim, Choi, et al. Diagnostic performance of liver fibrosis assessment by quantification of liver surface nodularity on computed tomography and magnetic resonance imaging: systematic review and meta-analysis. Eur Radiol. 2022. PMID: 35043290. doi:10.1007/s00330-021-08436-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。